Abstract
Mycobacterium tuberculosis (Mtb), due to its unusual organization crosses different immune barriers and causes tuberculosis. The advent of multidrug resistance tuberculosis (MDR-TB) has attained alarming situation. Hence, computational drug design has been performed in this work to find potent molecules for this purpose.
Isoniazid is a widely used frontline drug against tuberculosis. But reports justified the inactivity of isoniazid on acetylation by Arylamine N-acetyltransferase (NAT). 35 countries were highlighted to have isoniazid resistance from survey in 1998. Hence, Mtb NAT has been selected as the target in the present case and hundred compounds were screened in order to find potent NAT inhibitor to raise the efficacy of isoniazid.
Molecular docking with Biosolveit LeadIT and Autodock 4.2 simulation was performed. The result showed 7- methylpicene-1, 2-diol to have -26.77 and -8.26 kcal/mol score in LeadIT and Autodock 4.2. The work validated 7- methylpicene-1, 2-diol to be a potent NAT inhibitor to supplement isoniazid.
Keywords: Anti-tubercular drug, Arylamine N-acetyltransferase, isoniazid, MDR-TB, NAT, 7-methylpicene-1, 2-diol.
Combinatorial Chemistry & High Throughput Screening
Title:High Throughput Screening of 7-Methylpicene-1,2-Diol as Arylamine N-Acetyltransferase (NAT) Inhibitor to Establish a Isoniazid Supplement in Anti-Tubercular Therapy
Volume: 16 Issue: 9
Author(s): Abhishek Chowdhury, Paulomi Paul and Manabendra Dutta Choudhury
Affiliation:
Keywords: Anti-tubercular drug, Arylamine N-acetyltransferase, isoniazid, MDR-TB, NAT, 7-methylpicene-1, 2-diol.
Abstract: Mycobacterium tuberculosis (Mtb), due to its unusual organization crosses different immune barriers and causes tuberculosis. The advent of multidrug resistance tuberculosis (MDR-TB) has attained alarming situation. Hence, computational drug design has been performed in this work to find potent molecules for this purpose.
Isoniazid is a widely used frontline drug against tuberculosis. But reports justified the inactivity of isoniazid on acetylation by Arylamine N-acetyltransferase (NAT). 35 countries were highlighted to have isoniazid resistance from survey in 1998. Hence, Mtb NAT has been selected as the target in the present case and hundred compounds were screened in order to find potent NAT inhibitor to raise the efficacy of isoniazid.
Molecular docking with Biosolveit LeadIT and Autodock 4.2 simulation was performed. The result showed 7- methylpicene-1, 2-diol to have -26.77 and -8.26 kcal/mol score in LeadIT and Autodock 4.2. The work validated 7- methylpicene-1, 2-diol to be a potent NAT inhibitor to supplement isoniazid.
Export Options
About this article
Cite this article as:
Chowdhury Abhishek, Paul Paulomi and Choudhury Dutta Manabendra, High Throughput Screening of 7-Methylpicene-1,2-Diol as Arylamine N-Acetyltransferase (NAT) Inhibitor to Establish a Isoniazid Supplement in Anti-Tubercular Therapy, Combinatorial Chemistry & High Throughput Screening 2013; 16 (9) . https://dx.doi.org/10.2174/13862073113169990004
DOI https://dx.doi.org/10.2174/13862073113169990004 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Quorum Sensing Inhibitors from the Sea: Lessons from Marine Symbiotic Relationships
Current Organic Chemistry Strain Typing of Mycoplasma pneumoniae and its Value in Epidemiology
Current Pediatric Reviews Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery New Insights into Chemistry and Anti-Infective Potential of Triazole Scaffold
Current Medicinal Chemistry Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research Recent Achievements in the Chemistry of 1,2-Diazines
Current Organic Chemistry A Concise Overview on Recent Advances in Pharmaceutical Aerosols and their Commercial Applications
Current Materials Science Nanoemulsion Formulation Enhances Intracellular Activity of Capuramycin Analogues against Mycobacterium Tuberculosis
Drug Delivery Letters The Use of Affinity Tags to Overcome Obstacles in Recombinant Protein Expression and Purification
Protein & Peptide Letters Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome<sup>#</sup>
Current Pharmaceutical Design Prediction of Microbe-drug Associations Based on Chemical Structures and the KATZ Measure
Current Bioinformatics Diversity and Functionality of Mycobacterial Mycolic Acids in Relation to Host-pathogen Interactions
Current Medicinal Chemistry The Structure - Antituberculosis Activity Relationships Study in a Series of 5-(4-Aminophenyl)-4-Substituted-2,4-Dihydro-3h-1,2,4-Triazole-3-Thione Derivatives. A Combined Electronic-Topological and Neural Networks Approach
Medicinal Chemistry Antibiotic use Evaluation in Hospitalized Pediatric Patients with Respiratory Tract Infections: A Retrospective Chart Review Study
Current Drug Safety Epoxide Hydrolases and their Application in Organic Synthesis
Current Organic Chemistry Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy